Title: “Is MASLD/MASH an insulin resistance disease?”

Dr. Najjar has disclosed the following financial relationships: none
Committee Members: Rachelle Lawhorn, Jeonga Kim, PhD, Anath Shalev, MD, and Sushant Bhatnagar, PhD have no relevant financial relationships related to the content of this continuing medical education activity to disclose.

Dr. W. Timothy Garvey has disclosed the following financial relationships: Grants/research support: Sanofi, Pfizer, Novo Nordisk; Consulting fee: Novo Nordisk, AMGEN, Gilead, Sanofi, American Medical Group Association, BOYDSense.; Stock/shareholder: Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, Merck.

The University of Alabama School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Alabama School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 credit™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.

IN PERSON MEETING
Date & Time
January 18, 2023 12:00-1:30pm (CST)
Location
School of Health Professions Building
LRC/SHPB 226
1716 9th Ave S, Birmingham, AL 35233
*Box Lunches will be served